Structural biology of SARS-CoV-1/SARS-CoV-2 main protease

References

• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767.
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81:853–879.
   PubMed Web of Science ®Google Scholar
• Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11:5047.
   PubMed Web of Science ®Google Scholar
• Günther S, Reinke PYA, Fernández-García Y, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021;372:642–646.
   PubMed Web of Science ®Google Scholar
• Matthews DA, Smith WW, Ferre RA, et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell. 1994;77:761–771.
   PubMed Web of Science ®Google Scholar
• Mosimann SC, Cherney MM, Sia S, et al. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J Mol Biol. 1997;273:1032–1047.
   PubMed Web of Science ®Google Scholar
• Hegyi A, Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J Gen Virol. 2002;83:595–599.
   PubMed Web of Science ®Google Scholar
• Hegyi A, Friebe A, Gorbalenya AE, et al. Mutational analysis of the active centre of coronavirus 3C-like proteases. J Gen Virol. 2002;83:581–593.
   PubMed Web of Science ®Google Scholar
• Ziebuhr J, Heusipp G, Siddell SG. Biosynthesis,: purification, and characterization of the human coronavirus 229E 3C-like proteinase. J Virol. 1997;71:3992–3997.
   PubMed Web of Science ®Google Scholar
• Anand K, Palm GJ, Mesters JR, et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002;21:3213–3224.
   PubMed Web of Science ®Google Scholar
• Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966.
   PubMed Web of Science ®Google Scholar
• Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol. 2004;7:412–419.
   PubMed Web of Science ®Google Scholar
• Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA. 2003;100:13190–13195.
   PubMed Web of Science ®Google Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293.
   PubMed Web of Science ®Google Scholar
• Qin E, Zhu Q, Yu M, et al. A complete sequence and comparative analysis of a SARS-associated virus (Isolate BJ01). Chin Sci Bull. 2003;48:941–948.
   PubMedGoogle Scholar
• Hsu M-F, Kuo C-J, Chang K-T, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem. 2005;280:31257–31266.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Xi K, Ratia K, et al. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors. J Med Chem. 2005;48:6767–6771.
   PubMed Web of Science ®Google Scholar
• Pyrc K, Berkhout B, van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol. 2007;81:3051–3057.
   PubMed Web of Science ®Google Scholar
• Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
   PubMed Web of Science ®Google Scholar
• Shi J, Sivaraman J, Song J. Mechanism for controlling the dimer-monomer switch and coupling dimerization to catalysis of the severe acute respiratory syndrome coronavirus 3C-like protease. J Virol. 2008;82:4620–4629.
   PubMed Web of Science ®Google Scholar
• Tan J, Verschueren KHG, Anand K, et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol. 2005;354:25–40.
   PubMed Web of Science ®Google Scholar
• Xue X, Yu H, Yang H, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82:2515–2527.
   PubMed Web of Science ®Google Scholar
• Hu T, Zhang Y, Li L, et al. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology. 2009;388:324–334.
   PubMed Web of Science ®Google Scholar
• Barrila J, Gabelli SB, Bacha U, et al. Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL(pro). Biochemistry. 2010;49:4308–4317.
   PubMed Web of Science ®Google Scholar
• Muramatsu T, Takemoto C, Kim Y-T, et al. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc Natl Acad Sci USA. 2016;113:12997–13002.
   PubMed Web of Science ®Google Scholar
• Yang H, Xie W, Xue X, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3:e324.
   PubMed Web of Science ®Google Scholar
• Lee T-W, Cherney MM, Huitema C, et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J Mol Biol. 2005;353:1137–1151.
   PubMed Web of Science ®Google Scholar
• Lu I-L, Mahindroo N, Liang P-H, et al. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem. 2006;49:5154–5161.
   PubMed Web of Science ®Google Scholar
• Verschueren KHG, Pumpor K, Anemüller S, et al. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. Chem Biol. 2008;15:597–606.
   PubMedGoogle Scholar
• Akaji K, Konno H, Mitsui H, et al. Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors. J Med Chem. 2011;54:7962–7973.
   PubMedGoogle Scholar
• Zhu L, George S, Schmidt MF, et al. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Res. 2011;92:204–212.
   PubMed Web of Science ®Google Scholar
• Jacobs J, Grum-Tokars V, Zhou Y, et al. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem. 2013;56:534–546.
   PubMed Web of Science ®Google Scholar
• Chuck C-P, Chen C, Ke Z, et al. Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. Eur J Med Chem. 2013;59:1–6.
   PubMed Web of Science ®Google Scholar
• Turlington M, Chun A, Tomar S, et al. Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorg Med Chem Lett. 2013;23:6172–6177.
   PubMed Web of Science ®Google Scholar
• Shimamoto Y, Hattori Y, Kobayashi K, et al. Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors. Bioorg Med Chem. 2015;23:876–890.
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
   PubMed Web of Science ®Google Scholar
• Roe MK, Junod NA, Young AR, et al. Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19. J Gen Virol. 2021;102:001558.
   PubMed Web of Science ®Google Scholar
• Luttens A, Gullberg H, Abdurakhmanov E, et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J Am Chem Soc. 2022;144:2905–2920.
   PubMed Web of Science ®Google Scholar
• Antonopoulou I, Sapountzaki E, Rova U, et al. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Comput Struct Biotechnol J. 2022;20:1306–1344.
   PubMed Web of Science ®Google Scholar
• Jaskolski M, Dauter Z, Shabalin IG, et al. Crystallographic models of SARS-CoV-2 3CLpro: in-depth assessment of structure quality and validation. IUCrJ. 2021;8:238–256.
   PubMed Web of Science ®Google Scholar
• Tekpinar M, Yildirim A. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases. J Biomol Struct Dyn. 2022;40:6243–6254.
   PubMed Web of Science ®Google Scholar
• Wang H, He S, Deng W, et al. Comprehensive insights into the catalytic mechanism of Middle East respiratory syndrome 3C-like protease and severe acute respiratory syndrome 3C-like protease. ACS Catal. 2020;10:5871–5890.
   PubMed Web of Science ®Google Scholar
• Komatsu TS, Okimoto N, Koyama YM, et al. Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. Sci Rep. 2020;10:16986.
   PubMedGoogle Scholar
• Xiong M, Su H, Zhao W, et al. What coronavirus 3C-like protease tells us: from structure, substrate selectivity, to inhibitor design. Med Res Rev. 2021;41:1965–1998.
   PubMed Web of Science ®Google Scholar
• Huang C, Wei P, Fan K, et al. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry. 2004;43:4568–4574.
   PubMed Web of Science ®Google Scholar
• Paasche A, Zipper A, Schäfer S, et al. Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease. Biochemistry. 2014;53:5930–5946.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Phillips G, Weiss KL, et al. Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography. J Biol Chem. 2020;295:17365–17373.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Phillips G, O’Neill HM, et al. Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: insights into enzyme mechanism and drug design. IUCrJ. 2020;7:1028–1035.
   PubMed Web of Science ®Google Scholar
• Lee J, Worrall LJ, Vuckovic M, et al. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nat Commun. 2020;11:5877.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Phillips G, O’Neill HM, et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020;11:3202.
   PubMed Web of Science ®Google Scholar
• Ménard R, Storer AC. Oxyanion hole interactions in serine and cysteine proteases. Biol Chem Hoppe-Seyler. 1992;373:393–400.
   PubMed Web of Science ®Google Scholar
• Chen S, Hu T, Zhang J, et al. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations. J Biol Chem. 2008;283:554–564.
   PubMed Web of Science ®Google Scholar
• Dai W, Zhang B, Jiang X-M, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331–1335.
   PubMed Web of Science ®Google Scholar
• Hattori S-I, Higashi-Kuwata N, Hayashi H, et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2021;12:668.
   PubMed Web of Science ®Google Scholar
• Yang KS, Ma XR, Ma Y, et al. A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors. ChemMedChem. 2021;16:942–948.
   PubMed Web of Science ®Google Scholar
• MacDonald EA, Frey G, Namchuk MN, et al. Recognition of divergent viral substrates by the SARS-CoV-2 main protease. ACS Infect Dis. 2021;7:2591–2595.
   PubMed Web of Science ®Google Scholar
• Hoffman RL, Kania RS, Brothers MA, et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem. 2020;63:12725–12747.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Xi K, Grum-Tokars V, et al. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett. 2007;17:5876–5880.
   PubMed Web of Science ®Google Scholar
• Zhang C-H, Stone EA, Deshmukh M, et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent Sci. 2021;7:467–475.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Kusov Y, et al. α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. J Med Chem. 2020;63:4562–4578.
   PubMed Web of Science ®Google Scholar
• Hsu W-C, Chang H-C, Chou C-Y, et al. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J Biol Chem. 2005;280:22741–22748.
   PubMed Web of Science ®Google Scholar
• Chou C-Y, Chang H-C, Hsu W-C, et al. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry. 2004;43:14958–14970.
   PubMed Web of Science ®Google Scholar
• Zhong N, Zhang S, Zou P, et al. Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain. J Virol. 2008;82:4227–4234.
   PubMed Web of Science ®Google Scholar
• Zhong N, Zhang S, Xue F, et al. C-terminal domain of SARS-CoV main protease can form a 3D domain-swapped dimer. Protein Sci. 2009;18:839–844.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhang J, Hu T, et al. Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis. J Biochem. 2008;143:525–536.
   PubMed Web of Science ®Google Scholar
• Shan Y-F, Li S-F, Xu G-J. A novel auto-cleavage assay for studying mutational effects on the active site of severe acute respiratory syndrome coronavirus 3C-like protease. Biochem Biophys Res Commun. 2004;324:579–583.
   PubMed Web of Science ®Google Scholar
• Ullrich S, Ekanayake KB, Otting G, et al. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022;62:128629.
   PubMed Web of Science ®Google Scholar
• Lin P-Y, Chou C-Y, Chang H-C, et al. Correlation between dissociation and catalysis of SARS-CoV main protease. Arch Biochem Biophys. 2008;472:34–42.
   PubMed Web of Science ®Google Scholar
• Noske GD, Nakamura AM, Gawriljuk VO, et al. A crystallographic snapshot of SARS-CoV-2 main protease maturation process. J Mol Biol. 2021;433:167118.
   PubMed Web of Science ®Google Scholar
• Sun Z, Wang L, Li X, et al. An extended conformation of SARS-CoV-2 main protease reveals allosteric targets. Proc Natl Acad Sci USA. 2022;119:e2120913119.
   PubMed Web of Science ®Google Scholar
• Ebrahim A, Riley BT, Kumaran D, et al. The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M pro). BioRxiv. 2021.
   Google Scholar
• Pearce NM, Gros P. A method for intuitively extracting macromolecular dynamics from structural disorder. Nat Commun. 2021;12:5493.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem. 2016;59:5172–5208.
   PubMed Web of Science ®Google Scholar
• de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis. 2017;5:Doc08.
   PubMedGoogle Scholar
• Zephyr J, Kurt Yilmaz N, Schiffer CA. Viral proteases: structure, mechanism and inhibition. Enzymes. 2021;50:301–333.
   PubMedGoogle Scholar
• Lee C-C, Kuo C-J, Ko T-P, et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J Biol Chem. 2009;284:7646–7655.
   PubMed Web of Science ®Google Scholar
• Lee T-W, Cherney MM, Liu J, et al. Crystal structures reveal an induced-fit binding of a substrate-like Aza-peptide epoxide to SARS coronavirus main peptidase. J Mol Biol. 2007;366:916–932.
   PubMed Web of Science ®Google Scholar
• Yang S, Chen S-J, Hsu M-F, et al. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem. 2006;49:4971–4980.
   PubMed Web of Science ®Google Scholar
• Bai B, Belovodskiy A, Hena M, et al. Peptidomimetic α-acyloxymethylketone warheads with six-membered lactam P1 glutamine mimic: SARS-CoV-2 3CL protease inhibition, coronavirus antiviral activity, and in vitro biological stability. J Med Chem. 2022;65:2905–2925.
   PubMed Web of Science ®Google Scholar
• Yin J, Niu C, Cherney MM, et al. A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase. J Mol Biol. 2007;371:1060–1074.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409–412.
   PubMed Web of Science ®Google Scholar
• Rathnayake AD, Zheng J, Kim Y, et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci Transl Med. 2020;12:eabc5332.
   PubMed Web of Science ®Google Scholar
• Dampalla CS, Kim Y, Bickmeier N, et al. Structure-guided design of conformationally constrained cyclohexane inhibitors of severe acute respiratory syndrome coronavirus-2 3CL protease. J Med Chem. 2021;64:10047–10058.
   PubMed Web of Science ®Google Scholar
• Dampalla CS, Rathnayake AD, Perera KD, et al. Structure-guided design of potent inhibitors of SARS-CoV-2 3CL protease: structural, biochemical, and cell-based studies. J Med Chem. 2021;64:17846–17865.
   PubMed Web of Science ®Google Scholar
• Vuong W, Khan MB, Fischer C, et al. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2020;11:4282.
   PubMed Web of Science ®Google Scholar
• Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv. 2020;6:eabe0751.
   PubMed Web of Science ®Google Scholar
• Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020;11:4417.
   PubMed Web of Science ®Google Scholar
• Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678–692.
   PubMed Web of Science ®Google Scholar
• Arutyunova E, Khan MB, Fischer C, et al. N-Terminal finger stabilizes the S1 pocket for the reversible feline drug GC376 in the SARS-CoV-2 Mpro dimer. J Mol Biol. 2021;433:167003.
   PubMed Web of Science ®Google Scholar
• Shi Y, Shuai L, Wen Z, et al. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. Emerg Microbes Infect. 2021;10:481–492.
   PubMed Web of Science ®Google Scholar
• Vuong W, Fischer C, Khan MB, et al. Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: structural enhancements, increased solubility, and micellar studies. Eur J Med Chem. 2021;222:113584.
   PubMed Web of Science ®Google Scholar
• Liu H, Iketani S, Zask A, et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun. 2022;13:1891.
   PubMed Web of Science ®Google Scholar
• Bacha U, Barrila J, Gabelli SB, et al. Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CL(pro). Chem Biol Drug Des. 2008;72:34–49.
   PubMed Web of Science ®Google Scholar
• Ullrich S, Sasi VM, Mahawaththa MC, et al. Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. Bioorg Med Chem Lett. 2021: 128333.
   PubMed Web of Science ®Google Scholar
• Amporndanai K, Meng X, Shang W, et al. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat Commun. 2021;12:3061.
   PubMed Web of Science ®Google Scholar
• Su H, Yao S, Zhao W, et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun. 2021;12:3623.
   PubMed Web of Science ®Google Scholar
• Kitamura N, Sacco MD, Ma C, et al. Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors. J Med Chem. 2022;65:2848–2865.
   PubMed Web of Science ®Google Scholar
• Mslati H, Gentile F, Perez C, et al. Comprehensive consensus analysis of SARS-CoV-2 drug repurposing campaigns. J Chem Inf Model. 2021;61:3771–3788.
   PubMed Web of Science ®Google Scholar
• Lockbaum GJ, Reyes AC, Lee JM, et al. Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses. 2021;13.
   PubMed Web of Science ®Google Scholar
• Deshmukh MG, Ippolito JA, Zhang C-H, et al. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease. Structure. 2021;29:823–833.e5.
   PubMed Web of Science ®Google Scholar
• Clyde A, Galanie S, Kneller DW, et al. High-throughput virtual screening and validation of a SARS-CoV-2 main protease noncovalent inhibitor. J Chem Inf Model. 2022;62:116–128.
   PubMed Web of Science ®Google Scholar
• Redhead MA, Owen CD, Brewitz L, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021;11:13208.
   PubMed Web of Science ®Google Scholar
• Iketani S, Forouhar F, Liu H, et al. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun. 2021;12:2016.
   PubMed Web of Science ®Google Scholar
• Gimeno A, Mestres-Truyol J, Ojeda-Montes MJ, et al. Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition. Int J Mol Sci. 2020;21:3793.
   PubMed Web of Science ®Google Scholar
• Han SH, Goins CM, Arya T, et al. Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro). J Med Chem. 2022;65:2880–2904.
   PubMed Web of Science ®Google Scholar
• Llanos MA, Gantner ME, Rodriguez S, et al. Strengths and weaknesses of docking simulations in the SARS-CoV-2 era: the main protease (Mpro) case study. J Chem Inf Model. 2021;61:3758–3770.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Tokutomi S, Hatada R, et al. Dynamic cooperativity of ligand-residue interactions evaluated with the fragment molecular orbital method. J Phys Chem B. 2021;125:6501–6512.
   PubMed Web of Science ®Google Scholar
• Stille JK, Tjutrins J, Wang G, et al. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. Eur J Med Chem. 2022;229:114046.
   PubMed Web of Science ®Google Scholar
• Zaidman D, Gehrtz P, Filep M, et al. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Cell Chem Biol. 2021;28:1795–1806.e5.
   PubMed Web of Science ®Google Scholar
• Unoh Y, Uehara S, Nakahara K, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499–6512.
   PubMed Web of Science ®Google Scholar
• Shionogi Co., Ltd. New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance. News. Shionogi Co., Ltd. [Internet]. [cited 2022 May 3]. Available from: https://www.shionogi.com/global/en/news/2022/04/20220424.html.
   Google Scholar
• Su H-X, Yao S, Zhao W-F, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020;41:1167–1177.
   PubMed Web of Science ®Google Scholar
• Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020;27:529–532.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou X, Zhang Y, et al. Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode. Sci Bull (Beijing). 2021;66:661–663.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Galanie S, Phillips G, et al. Malleability of the SARS-CoV-2 3CL Mpro active-site cavity facilitates binding of clinical antivirals. Structure. 2020;28:1313–1320.e3.
   PubMed Web of Science ®Google Scholar
• Bai Y, Ye F, Feng Y, et al. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduct Target Ther. 2021;6:51.
   PubMed Web of Science ®Google Scholar
• Qiao J, Li Y-S, Zeng R, et al. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model. Science. 2021;371:1374–1378.
   PubMed Web of Science ®Google Scholar
• Oerlemans R, Ruiz-Moreno AJ, Cong Y, et al. Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics. RSC Med Chem. 2020;12:370–379.
   PubMedGoogle Scholar
• Drayman N, DeMarco JK, Jones KA, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021;373:931–936.
   PubMed Web of Science ®Google Scholar
• Dementiev A, Joachimiak A, Nguyen H, et al. Molecular mechanism of inhibition of acid ceramidase by carmofur. J Med Chem. 2019;62:987–992.
   PubMed Web of Science ®Google Scholar
• Ma C, Hu Y, Townsend JA, et al. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin Are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol Transl Sci. 2020;3:1265–1277.
   PubMedGoogle Scholar
• Baker JD, Uhrich RL, Kraemer GC, et al. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease. PLoS ONE. 2021;16:e0245962.
   PubMed Web of Science ®Google Scholar
• Xia Z, Sacco M, Hu Y, et al. Rational design of hybrid SARS-CoV-2 main protease inhibitors guided by the superimposed cocrystal structures with the peptidomimetic inhibitors GC-376, telaprevir, and boceprevir. ACS Pharmacol Transl Sci. 2021;4:1408–1421.
   PubMedGoogle Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593.
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Foo CS, Jochmans D, et al. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nat Commun. 2022;13:719.
   PubMed Web of Science ®Google Scholar
• Li J, Lin C, Zhou X, et al. Structural basis of the main proteases of coronavirus bound to drug candidate PF-07321332. J Virol. 2022;96:e0201321.
   PubMed Web of Science ®Google Scholar
• Goetz DH, Choe Y, Hansell E, et al. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. Biochemistry. 2007;46:8744–8752.
   PubMed Web of Science ®Google Scholar
• Konno S, Kobayashi K, Senda M, et al. 3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents. J Med Chem. 2022;65:2926–2939.
   PubMed Web of Science ®Google Scholar
• Li J, Lin C, Zhou X, et al. Structural basis of main proteases of coronavirus bound to drug candidate PF-07304814. J Mol Biol. 2022;434:167706.
   PubMed Web of Science ®Google Scholar
• Ma Y, Yang KS, Geng ZZ, et al. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. Eur J Med Chem. 2022;240:114570.
   PubMed Web of Science ®Google Scholar
• Bai B, Arutyunova E, Khan MB, et al. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. RSC Med Chem. 2021;12:1722–1730.
   PubMedGoogle Scholar
• Sacco MD, Hu Y, Gongora MV, et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022;32:498–500.
   PubMed Web of Science ®Google Scholar
• Dampalla CS, Rathnayake AD, Galasiti Kankanamalage AC, et al. Structure-guided design of potent spirocyclic inhibitors of severe acute respiratory syndrome coronavirus-2 3C-like protease. J Med Chem. 2022;65:7818–7832.
   PubMed Web of Science ®Google Scholar
• Lee C-C, Kuo C-J, Hsu M-F, et al. Structural basis of mercury- and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. FEBS Lett. 2007;581:5454–5458.
   PubMed Web of Science ®Google Scholar
• Pillaiyar T, Flury P, Krüger N, et al. Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure-activity relationships, antiviral activity, and X-ray structure determination. J Med Chem. 2022;65:9376–9395.
   PubMedGoogle Scholar
• Fu L, Shao S, Feng Y, et al. Mechanism of microbial metabolite leupeptin in the treatment of COVID-19 by traditional Chinese medicine herbs. MBio. 2021;12:e0222021.
   PubMed Web of Science ®Google Scholar
• Andi B, Kumaran D, Kreitler DF, et al. Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. Sci Rep. 2022;12:12197.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Phillips G, Weiss KL, et al. Direct observation of protonation state modulation in SARS-CoV-2 main protease upon inhibitor binding with neutron crystallography. J Med Chem. 2021;64:4991–5000.
   PubMed Web of Science ®Google Scholar
• Lockbaum GJ, Henes M, Lee JM, et al. Pan-3C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode. Biochemistry. 2021;60:2925–2931.
   PubMed Web of Science ®Google Scholar
• Kuzikov M, Costanzi E, Reinshagen J, et al. Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in vitro repurposing screen. ACS Pharmacol Transl Sci. 2021;4:1096–1110.
   PubMedGoogle Scholar
• Costanzi E, Kuzikov M, Esposito F, et al. Structural and biochemical analysis of the dual inhibition of MG-132 against SARS-CoV-2 main protease (Mpro/3CLpro) and human cathepsin-L. Int J Mol Sci. 2021;22:11779.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Raghavaiah J, Shahabi D, et al. Indole chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure-activity relationship, and X-ray structural studies. J Med Chem. 2021;64:14702–14714.
   PubMed Web of Science ®Google Scholar
• Malla TR, Brewitz L, Muntean D-G, et al. Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine. J Med Chem. 2022;65:7682–7696.
   PubMed Web of Science ®Google Scholar
• Ma C, Xia Z, Sacco MD, et al. Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity. J Am Chem Soc. 2021;143:20697–20709.
   PubMed Web of Science ®Google Scholar
• Alugubelli YR, Geng ZZ, Yang KS, et al. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. Eur J Med Chem. 2022;240:114596.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Fang C, Zhang Q, et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2022;13:689–693.
   PubMed Web of Science ®Google Scholar
• Kneller D, Li H, Phillips G, et al. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity. [Preprint]. Res Sq. 2022.
   Google Scholar
• Greasley SE, Noell S, Plotnikova O, et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem. 2022: 101972.
   PubMedGoogle Scholar
• Xiong M, Nie T, Shao Q, et al. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease. Eur J Med Chem. 2022;231:114130.
   PubMed Web of Science ®Google Scholar
• Cantrelle F-X, Boll E, Brier L, et al. NMR spectroscopy of the main protease of SARS-CoV-2 and fragment-based screening identify three protein hotspots and an antiviral fragment. Angew Chem Int Ed. 2021;60:25428–25435.
   PubMed Web of Science ®Google Scholar
• Kneller DW, Li H, Galanie S, et al. Structural, electronic, and electrostatic determinants for inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease. J Med Chem. 2021;64:17366–17383.
   PubMed Web of Science ®Google Scholar
• Zhong B, Peng W, Du S, et al. Oridonin inhibits sars-cov-2 by targeting its 3c-like protease. Small Sci. 2022;2:2100124.
   PubMedGoogle Scholar
• Rossetti GG, Ossorio MA, Rempel S, et al. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Sci Rep. 2022;12:2505.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao H, Hu X, et al. Structure-based discovery and structural basis of a novel broad-spectrum natural product against the main protease of coronavirus. J Virol. 2022;96:e0125321.
   PubMed Web of Science ®Google Scholar
• Yang KS, Alex Kuo S-T, Blankenship LR, et al. Repurposing halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease. Curr Res Chem Biol. 2022;2:100025.
   PubMedGoogle Scholar
• Shaqra AM, Zvornicanin SN, Huang QYJ, et al. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun. 2022;13:3556.
   PubMed Web of Science ®Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. Antiviral Res. 2022;198:105252.
   PubMed Web of Science ®Google Scholar
• Sidebottom DB, Smith DD, Gill D. Safety and efficacy of antivirals against SARS-CoV-2. Br Med J. 2021;375:n2611.
   PubMedGoogle Scholar
• Ye C, Bian P, Zhang J, et al. Structure-based discovery of antiviral inhibitors targeting the E dimer interface of Japanese encephalitis virus. Biochem Biophys Res Commun. 2019;515:366–371.
   PubMed Web of Science ®Google Scholar
• Pietrucci F, Vargiu AV, Kranjc A. HIV-1 Protease dimerization dynamics reveals a transient druggable binding pocket at the interface. Sci Rep. 2015;5:18555.
   PubMed Web of Science ®Google Scholar
• Bannwarth L, Kessler A, Pèthe S, et al. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization. J Med Chem. 2006;49:4657–4664.
   PubMed Web of Science ®Google Scholar
• Brzezinski D, Kowiel M, Cooper DR, et al. Covid-19.bioreproducibility.org: A web resource for SARS-CoV-2-related structural models. Protein Sci. 2021;30:115–124.
   PubMed Web of Science ®Google Scholar
• Croll TI, Diederichs K, Fischer F, et al. Making the invisible enemy visible. Nat Struct Mol Biol. 2021;28:404–408.
   PubMed Web of Science ®Google Scholar
• Guven O, Gul M, Ayan E, et al. Case study of high-throughput drug screening and remote data collection for SARS-CoV-2 main protease by using serial femtosecond X-ray crystallography. Crystals. 2021;11:1579.
   Web of Science ®Google Scholar
• Chamakuri S, Lu S, Ucisik MN, et al. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors. Proc Natl Acad Sci USA. 2021;118:e2111172118.
   PubMed Web of Science ®Google Scholar
• Gildea RJ, Beilsten-Edmands J, Axford D, et al. Xia2.multiplex: a multi-crystal data-analysis pipeline. Acta Crystallogr D Struct Biol. 2022;78:752–769.
   PubMedGoogle Scholar
• Narayanan A, Narwal M, Majowicz SA, et al. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun Biol. 2022;5:169.
   PubMed Web of Science ®Google Scholar
• Sutanto F, Shaabani S, Oerlemans R, et al. Combining high-throughput synthesis and high-throughput protein crystallography for accelerated Hit identification. Angew Chem Int Ed. 2021;60:18231–18239.
   PubMed Web of Science ®Google Scholar
• Deetanya P, Hengphasatporn K, Wilasluck P, et al. Interaction of 8-anilinonaphthalene-1-sulfonate with SARS-CoV-2 main protease and its application as a fluorescent probe for inhibitor identification. Comput Struct Biotechnol J. 2021;19:3364–3371.
   PubMed Web of Science ®Google Scholar
• Moghadasi SA, Esler MA, Otsuka Y, et al. Gain-of-signal assays for probing inhibition of SARS-CoV-2 Mpro/3CLpro in living cells. MBio. 2022;13:e0078422.
   PubMed Web of Science ®Google Scholar
• Tomasello G, Armenia I, Molla G. The protein imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities. Bioinformatics. 2020;36:2909–2911.
   PubMed Web of Science ®Google Scholar
• Omasits U, Ahrens CH, Müller S, et al. Protter: interactive protein feature visualization and integration with experimental proteomic data. Bioinformatics. 2014;30:884–886.
   PubMed Web of Science ®Google Scholar